A carregar...
JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
The 2011 approval of ruxolitinib ushered in the Janus kinase (JAK) inhibitor era in the treatment of myelofibrosis (MF), and 2019 saw the US approval of fedratinib. The first therapeutic agents approved by regulatory authorities for MF, these drugs attenuate the overactive JAK-signal transducer and...
Na minha lista:
| Publicado no: | Hemasphere |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Health
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7375176/ https://ncbi.nlm.nih.gov/pubmed/32903304 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000424 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|